RO7239361

DRUG3 trials

Sponsors

Hoffmann-La Roche

Conditions

Duchenne Muscular DystrophyHealthyMuscular Dystrophy (DMD)

Phase 1

Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD

TerminatedNCT02515669

Hoffmann-La RocheMuscular Dystrophy (DMD)

Start: 2015-12-02End: 2020-04-15Updated: 2020-11-04

Compare Bioavailability of RO7239361 After Subcutaneous Injection

CompletedNCT03100630

Hoffmann-La RocheHealthy

Start: 2017-05-09End: 2017-10-17Updated: 2019-08-07

Phase 2

Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

CompletedNCT03039686

Hoffmann-La RocheDuchenne Muscular Dystrophy

Start: 2017-07-06End: 2020-04-28Updated: 2020-12-21

Related Papers

Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy.

2024-09-249 citations

The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy.

2024-01-0817 citations

Population <scp>PK</scp> and <scp>PD</scp> Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy

Clinical Pharmacology & Therapeutics2022-09-157 citations

A Phase 1b/2 Study of the Anti-Myostatin Adnectin RG6206 (BMS-986089) in Ambulatory Boys with Duchenne Muscular Dystrophy: A 72-Week Treatment Update (P1.6-062)

Neurology2019-04-096 citations

A randomized, placebo-controlled, double-blind, Phase 1b/2 study of the novel antimyostatin adnectin RG6206 (BMS-986089) in ambulatory boys with Duchenne muscular dystrophy (P5.431)

Neurology2018-04-103 citations